Sanofi & Teva Pharma's RELIEVE UCCD phase 2b study of duvakitug in ulcerative colitis and Crohn's disease meets primary ...
Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., announced that the RELIEVE UCCD phase 2b study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD). RELIEVE UCCD assessed …